41 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
and forecasting of our environmental data and performance, embed sustainability principles into the lifecycle of our therapies and build resilience
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs in the treatment of bleeding disorders, including through
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
TAKHZYRO, with continued investment in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs in the treatment
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
, including through TAKHZYRO, with continued investment in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs
6-K
TAK
Takeda Pharmaceutical Co
1 Aug 23
Current report (foreign)
6:10am
, Takeda aspires to transform the treatment paradigm, including through TAKHZYRO, with continued investment in lifecycle management programs. In rare
6-K
EX-99.1
2yqau9g16vq5qqf3xuvr
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
3iy8ug2c
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
pl9xo73
30 May 23
Current report (foreign)
6:11am
6-K
q84su
4 Nov 22
Current report (foreign)
6:01am
6-K
1lhb6of
4 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
nnopy7lqk
31 May 22
Current report (foreign)
6:14am
6-K
EX-99.1
vxfcw9 kb49bqrak7uq
31 May 22
Current report (foreign)
6:07am
6-K
uq0h2ll4exozx2 yb10c
11 May 22
Current report (foreign)
6:06am
6-K
pcgkgrfryt zlaftb
10 Feb 22
Current report (foreign)
6:03am
6-K
EX-99.1
tgrwuaka2khuq
11 Jan 22
Current report (foreign)
6:02am
6-K
y2nqs4uct9tj1175
5 Nov 21
Current report (foreign)
6:02am
6-K
1gab96acu36yx rd
6 Aug 21
Current report (foreign)
6:06am
6-K
EX-99.1
om4897kb 3z90b
29 Jun 21
Current report (foreign)
7:38am